Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Smith David Duane	2. Issuer Name and Ticker or Trading Symbol PHARMACYCLICS INC [ PCYC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 5/26/2015
(Street) SUNNYVALE, CA 94085 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.10	5/26/2015		D			7258	⁽¹⁾	1/4/2020	Common Stock	7258	⁽¹⁾	0	D
Stock Option (Right to Buy)	$2.90	5/26/2015		D			7500	⁽¹⁾	12/17/2019	Common Stock	7500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$6.63	5/26/2015		D			3393	⁽¹⁾	4/1/2020	Common Stock	3393	⁽¹⁾	0	D
Stock Option (Right to Buy)	$7.14	5/26/2015		D			1100	⁽¹⁾	8/6/2020	Common Stock	1100	⁽¹⁾	0	D
Stock Option (Right to Buy)	$6.75	5/26/2015		D			3333	⁽¹⁾	7/1/2020	Common Stock	3333	⁽¹⁾	0	D
Stock Option (Right to Buy)	$8.12	5/26/2015		D			2954	⁽¹⁾	10/1/2020	Common Stock	2954	⁽¹⁾	0	D
Stock Option (Right to Buy)	$6.52	5/26/2015		D			3680	⁽¹⁾	1/3/2021	Common Stock	3680	⁽¹⁾	0	D
Stock Option (Right to Buy)	$5.76	5/26/2015		D			7500	⁽¹⁾	12/9/2020	Common Stock	7500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$6.01	5/26/2015		D			4242	⁽¹⁾	4/1/2021	Common Stock	4242	⁽¹⁾	0	D
Stock Option (Right to Buy)	$10.58	5/26/2015		D			2409	⁽¹⁾	7/1/2021	Common Stock	2409	⁽¹⁾	0	D
Stock Option (Right to Buy)	$11.31	5/26/2015		D			2917	⁽¹⁾	10/3/2021	Common Stock	2917	⁽¹⁾	0	D
Stock Option (Right to Buy)	$14.26	5/26/2015		D			7500	⁽¹⁾	12/15/2021	Common Stock	7500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$15.02	5/26/2015		D			2480	⁽¹⁾	1/3/2022	Common Stock	2480	⁽¹⁾	0	D
Stock Option (Right to Buy)	$28.47	5/26/2015		D			1183	⁽¹⁾	4/2/2022	Common Stock	1183	⁽¹⁾	0	D
Stock Option (Right to Buy)	$59.28	5/26/2015		D			427	⁽¹⁾	7/2/2022	Common Stock	427	⁽¹⁾	0	D
Stock Option (Right to Buy)	$65.56	5/26/2015		D			431	⁽¹⁾	10/1/2022	Common Stock	431	⁽¹⁾	0	D
Stock Option (Right to Buy)	$49.00	5/26/2015		D			7500	⁽¹⁾	11/9/2022	Common Stock	7500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$61.44	5/26/2015		D			413	⁽¹⁾	1/2/2023	Common Stock	413	⁽¹⁾	0	D
Stock Option (Right to Buy)	$79.67	5/26/2015		D			298	⁽¹⁾	4/1/2023	Common Stock	298	⁽¹⁾	0	D
Stock Option (Right to Buy)	$74.48	5/26/2015		D			3750	⁽¹⁾	5/9/2023	Common Stock	3750	⁽¹⁾	0	D
Stock Option (Right to Buy)	$85.39	5/26/2015		D			313	⁽¹⁾	7/1/2023	Common Stock	313	⁽¹⁾	0	D
Stock Option (Right to Buy)	$139.89	5/26/2015		D			200	⁽¹⁾	10/1/2023	Common Stock	200	⁽¹⁾	0	D
Stock Option (Right to Buy)	$108.44	5/26/2015		D			217	⁽¹⁾	1/2/2024	Common Stock	217	⁽¹⁾	0	D
Stock Option (Right to Buy)	$107.42	5/26/2015		D			233	⁽¹⁾	4/1/2024	Common Stock	233	⁽¹⁾	0	D
Stock Option (Right to Buy)	$95.08	5/26/2015		D			3750	⁽¹⁾	5/9/2024	Common Stock	3750	⁽¹⁾	0	D
Stock Option (Right to Buy)	$89.58	5/26/2015		D			416	⁽¹⁾	7/1/2024	Common Stock	416	⁽¹⁾	0	D
Stock Option (Right to Buy)	$115.80	5/26/2015		D			308	⁽¹⁾	10/1/2024	Common Stock	308	⁽¹⁾	0	D
Stock Option (Right to Buy)	$124.46	5/26/2015		D			288	⁽¹⁾	1/2/2025	Common Stock	288	⁽¹⁾	0	D
Stock Option (Right to Buy)	$257.015	5/26/2015		D			166	⁽¹⁾	4/7/2025	Common Stock	166	⁽¹⁾	0	D

Explanation of Responses:

( 1)

Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Smith David Duane C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE, CA 94085	X

Signatures
/s/ David Smith		5/27/2015
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.